Download Files:

RO5461111

$285$7,800

Products Details

Product Description

– RO5461111 a highly specific and orally active antagonist of Cathepsin S with IC50s of 0.4 nM (human Cathepsin S) and 0.5 nM (murine Cathepsin S), respectively. RO5461111 can effectively inhibit the activation of antigen-specific T cells and B cells. RO5461111 can improve pulmonary inflammation and lupus nephritis[1][2].

Web ID

– HY-114374

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture and light)

Shipping

– Room Temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C27H24F6N4O4S

References

– [1]Sanchez RA, et al. Preparation of proline dipeptidyl nitrile derivatives as cathepsin, particularly cathepsin S and L, inhibitors: United States, US20100267722. 2010-10-21. |[2]Rupanagudi KV, et al. Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann Rheum Dis. 2015 Feb;74(2):452-63.

CAS Number

– 1252637-46-9

Molecular Weight

– 614.56

Compound Purity

– 98.17

SMILES

– O=C([C@H]1N(C(C2(C(F)(F)F)CC2)=O)C[C@H](S(=O)(C3=CC=C(C4=CC(C)=NC=C4)C=C3C(F)(F)F)=O)C1)NC5(C#N)CC5

Clinical Information

– No Development Reported

Research Area

– Inflammation/Immunology

Solubility

– 10 mM in DMSO

Target

– Cathepsin

Isoform

– Cathepsin S

Pathway

– Metabolic Enzyme/Protease

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.